A recent report by Moody’s Investor Service found that following regulatory crackdowns on the pharmaceutical market, the generic drug industry will likely experience rapid consolidation in the near future. According to Moody’s, the recent US Supreme Court decision, which found that drug makers can face lawsuits regarding pay-for-delay agreements, will lead to an influx of Federal Trade Commission scrutiny over the industry as well as class action litigation, many such cases have been on hold since before the Supreme Court ruling. The result, said Moody’s, means threats of large liabilities that – along with other factors – could lead generic drug makers to consolidate as purchasers and regulators seek damages. The report cites last week’s decision by Teva Pharmaceuticals to settle over such an antitrust case for $485 million.
Full Content: Forbes
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI